But seek medical attention if you experience any of the following alongside your sulfur burps: Severe or persistent vomiting
Key Findings 93.4% of patients would get bariatric surgery again 51.4% of patients would consider using GLP-1 drugs again 57.1% of GLP-1 patients reported losing at least 20 pounds 98.1% of bariatric surgery patients reported losing at least 20 pounds Median weight loss for bariatric surgery patients was 100 pounds, as opposed to 20 for GLP-1s Average weight loss for bariatric surgery was reported to be 101.2, as opposed to 24.9 for GLP-1 users 93.4% of Patients Would Get Bariatric Surgery Again Out of all patients surveyed, 93.4% said they would get bariatric surgery again
Researchers are also exploring their potential benefits for things like smoking cessation, substance use disorders, and even polycystic ovary syndrome (PCOS), widening their impact far beyond diabetes and obesity
In add-on therapy, starting with an SGLT2 inhibitor may be preferable, especially for patients with established diabetic kidney disease, owing to its well-documented benefits in reducing intraglomerular pressure and albuminuria
Lixisenatide is a daily GLP-1RA developed by Zealand Pharma, which prolongs its half-life through structure-inducing probe technology based on exendin-4/exenatide
Are GLP-1 weight-loss patches regulated by the FDA
